(1 - 12 from 30
)
| NDAQ:FRLN | Press Release - Stockhouse
stockhouse.com
Jun 14, — “The ultimate promise of gene therapy is a functional cure,” said Pamela Foulds, MD, Chief Medical Officer of Freeline. › press-releases ›
2nd Hem B Patient Group Begins Dosing in Gene Therapy Trial
hemophilianewstoday.com
Jun 15, — “The ultimate promise of gene therapy is a functional cure,” said Pamela Foulds, MD, chief medical officer of Freeline. › news
FLT190, Fabry Gene Therapy, Being Tested at Higher Dose in ...
fabrydiseasenews.com
Mar 25, — ... level without dosing a third patient at the lowest dose,” Pamela Foulds, MD, Freeline's chief medical officer, said in a press release. › news › flt190-gene-ther...
First Patient Dosed in Freeline's Dose-Confirmation Trial for ...
www.hemophilia.org
Mar 25, — ... and keep hemophilia B patients in the normal range of Factor IX expression, said Pamela Foulds, MD, Chief Medical Officer of Freeline. › news › first-patient-dosed...
sorted by relevance / date